Patients With Massive Transfusion: Who Are You?
Patients With Massive Transfusion: Who Are You?
复制标题
大量输血患者：你是谁？
DOI：
10.1097/ccm.0000000000001505
复制
发表时间：
2016
影响因子：
8.8
通讯作者：
Bennett-Guerrero,Elliott
中科院分区：
文献类型：
--
作者：
Bennett-Guerrero,Elliott
Editorials632 www. ccmjournal. org March 2016• Volume 44• Number 3 condition (eg, cancer). For example, 91.1% of patients who received MT in the setting of malignant disease (nonsurgical) died within 5 years. In contrast, in cases of MT during obstetrical hemorrhage, which generally occurs in young and healthy individuals, mortality was only 1.7% through 5 years. In addition, they also found that standardized mortality ratios (indexed to the general population) remained quite high even out to 5 to 10 years after the MT. This, however, does not imply causation between the receipt of many units of RBCs and long-term mortality because patients with more severe injury/illness who bleed significantly will certainly be at risk for complications, fore example, acute/renal failure, that will adversely impact their long-term prognosis. The authors were unable to assess whether the transfusions per se, independent of disease severity/comorbidities, were associated with adverse outcome.Bleeding and the need for transfusion are still major issues affecting ICU patients. The study by Halmin et al (10) is a step in the right direction because it will help focus our research and quality improvement efforts on the patients in whom MT is occurring most frequently.
